U.S. market Closed. Opens in 1 day 11 hours 29 minutes

KMDA | Kamada Ltd. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 5.83 - 5.99
52 Week Range 4.74 - 6.53
Beta 0.96
Implied Volatility 175.44%
IV Rank 42.26%
Day's Volume 17,574
Average Volume 36,050
Shares Outstanding 57,485,600
Market Cap 339,165,040
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
IPO Date 2013-05-31
Valuation
Profitability
Growth
Health
P/E Ratio 21.85
Forward P/E Ratio N/A
EPS 0.27
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 378
Country Israel
Website KMDA
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
*Chart delayed
Analyzing fundamentals for KMDA we got that it has average fundamentals where Valuation is considered to be undervalued, Profitability is unacceptably poor, Growth is on medium level and Health is strong. For more detailed analysis please see KMDA Fundamentals page.

Watching at KMDA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on KMDA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙